张清,赵英明,陈波,周芳,陈磊磊,许智慧,杨志健

• 1:南京医科大学附属淮安第一医院心内科
• 2:南京医科大学附属江苏省人民医院心内科

摘要(Abstract)：

目的回顾性分析常规剂量他汀类药物对既往有乙肝病毒(HBV)感染史的患者肝损害的影响,并探讨可能的机制。方法回顾性分析2005年10月—2008年09月江苏省人民医院心内科住院患者中服他汀类药物患者3125例,其中既往有HBV感染史174例,平均年龄66.60岁,男性131例;既往无HBV感染史166例,平均年龄65.81岁,男性131例,调查其服他汀后肝功能指标在短时期(2～15周)内的变化。比较两组的差异,分析出现差异的可能原因。结果丙氨酸转氨酶(ALT)升高大于正常上限(ULN)3倍而停药的比例,既往HBV感染组高于阴性组(2.87%比0.00%,χ2=0.1183,P=0.027),多因素回归分析示仅既往HBV感染史与服用他汀后ALT升高相关(β=11.77,sx珋=2.70,t=4.36,P=0.000)。结论既往有HBV感染史患者服用他汀类药物肝损害发生率增高,此类人群应加强肝功能监测。

关键词(KeyWords)： 他汀类;肝炎病毒,乙型

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张清,赵英明,陈波,周芳,陈磊磊,许智慧,杨志健

参考文献(References)：

• [1]Dujovne CA,Chremos AN,Pool JL,et al.Expanded clinical evaluation of lovastatin(EXCEL)study results:Ⅳ.Additional perspectives on the tolerability of lovastatin.Am J Med,1991,91:25S-30S.
• [2]Downs JR,Clearfield M,Weis S,et al Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA,1998,279:1615-1622.
• [3]Cohen DE,Anania FA,Chalasani N,et al.An assessment of statin safety by hepatologists.Am J Cardiol,2006,97:77C-81C.
• [4]Safeer RS.Can"statins"be used in patients with hepatitis B?Postgrad Med,2002,111:119-120.
• [5]Khorashadi S,Hasson NK,Cheung RC.Incidence of statin hepatotoxicity in patients with hepatitis C.Clin Gastroenterol Hepatol,2006,4:902-907.
• [6]Segarra-Newnham M,Parra D,Martin-Cooper EM.Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.Pharmacotherapy,2007,27:845-851.
• [7]Rallidis LS,Drakoulis CK,Parasi AS.Pravastatin in patients with nonalcoholic steatohepatitis:results of a pilot study.Atherosclerosis,2004,174:193-196.
• [8]Ekstedt M,Franzen LE,Mathiesen UL,et al.Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes:a histopathological follow-up study.J Hepatol,2007,47:135-141.
• [9]Lewis JH,Mortensen ME,Zweig S,et al.Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease:Results of a prospective,randomized,double-blind,placebo-controlled,multicenter trial.Hepatology,2007,46:1453-1463.
• [10]陈晓琳,彭婕,高爱慧.辛伐他汀致肝细胞性黄疸.药物不良反应杂志,2006,8:295.
• [11]陈虹,李岩.阿托伐他汀诱发乙型肝炎复发.药物不良反应杂志,2008,10:157.
• [12]Bjornsson E.Drug-induced liver injury:Hy's rule revisited.Clin Pharmacol Ther,2006,79:521-528.
• [13]中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2005,13:882.
• [14]范建高,蔡晓波.他汀类药物肝脏安全性问题.中华心血管病杂志,2007,35:589.
• [15]Jones P,Kafonek S,Laurora I,et al.Comparative dose efficacy study of atorvastatin versus simvastatin,pravastatin,lovastatin,and fluvastatin in patients with hypercholesterolemia(the CURVES study).Am J Cardiol,1998,81:582-587.
• [16]Watkins PB,Seeff LB.Drug-induced liver injury:summary of a single topic clinical research conference.Hepatology,2006,43:618-631.
• [17]Goldstein MR,Mascitelli L,Pezzetta F.The double-edged sword of statin immunomodulation.Int J Cardiol,2009,135:128-130.
• [18]Alla V,Abraham J,Siddiqui J,et al.Autoimmune hepatitis triggered by statins.J Clin Gastroenterol,2006,40:757-761.
• [19]van Heyningen C.Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.Ann Clin Biochem,2005,42:402-404.
• [20]Graziadei IW,Obermoser GE,Sepp NT,et al.Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.Lupus,2003,12:409-412.